Stockscreener 앱 받기
21.29
5.00%
-1.12
시간 외 거래:
21.50
0.21
+0.99%
전일 마감가:
$22.41
열려 있는:
$22.56
하루 거래량:
788.50K
Relative Volume:
1.34
시가총액:
$1.28B
수익:
$1.23M
순이익/손실:
$-214.90M
주가수익비율:
-5.1647
EPS:
-4.1222
순현금흐름:
$-151.25M
1주 성능:
-7.11%
1개월 성능:
-4.44%
6개월 성능:
-19.87%
1년 성능:
+3.96%
1일 변동 폭
$20.26
$22.86
1주일 범위
$20.26
$23.60
52주 변동 폭
$20.07
$47.97
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
SYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
21.29 | 1.28B | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at The Goldman Sachs Group - Defense World
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Can This Novel Dual-Action IBD Treatment Transform Patient Care? New Data Reveals Promising Results - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
1,955 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call - MSN
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? - MSN
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call By Investing.com - Investing.com
Spyre (SYRE) Unveils Strategic Talent Retention Plan: 35K Options with 10-Year Window - StockTitan
China Universal Asset Management Co. Ltd. Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - cnhinews.com
A company insider recently sold 6,700 shares of Spyre Therapeutics Inc [SYRE]. Should You also Consider to Sale? - Knox Daily
Financial Analysis: Spyre Therapeutics Inc (SYRE)’s Ratios Unveil Key Insights - The Dwinnex
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Oruka Therapeutics initiated with an Outperform at Wolfe Research - MSN
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
JPMorgan Chase & Co. Has $867,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Assenagon Asset Management S.A. Has $527,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Assenagon Asset Management S.A. Cuts Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $54.83 - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 9.4%Time to Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3%What's Next? - MarketBeat
Lifesci Capital Has Positive Outlook of SYRE FY2024 Earnings - Defense World
FY2024 EPS Forecast for Spyre Therapeutics Lifted by Analyst - MarketBeat
Get Caught Trying - Audacy
Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Given "Outperform" Rating at Wedbush - MarketBeat
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PR Newswire
Spyre Therapeutics Unveils Ambitious 2025 Pipeline Plans with $600M Cash Runway Through 2028 - StockTitan
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2%Here's Why - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Jane Street Group LLC - Defense World
Spyre Therapeutics Awards Key Employee Stock Options at $24.35 with 10-Year Term - StockTitan
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $51.50 - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Geode Capital Management LLC Has $26.21 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Geode Capital Management LLC Purchases 125,214 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Contrasting Spyre Therapeutics (NASDAQ:SYRE) & Generation Bio (NASDAQ:GBIO) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 2.5%Here's Why - MarketBeat
Barclays PLC Buys 41,424 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Barclays PLC Boosts Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):